A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Phase 2 Completed 51 enrolled Aldeyra Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindOther

Summary

The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.

Timeline

Start: 2017-05-15
Primary completion: 2017-07-06
Completion: 2017-07-06

Publications

Results Clark D, Sheppard J, Brady TC. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease. J Ocul Pharmacol Ther. 2021 May;37(4):193-199. doi: 10.1089/jop.2020.0087. Epub 2021 Jan 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Reproxalap	Other / unclassified	0.1 %	Topical
Subject	Reproxalap	Other / unclassified	0.5 %	Topical

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Summary

Timeline

Publications

Drugs

Indications